Feature|Videos|September 30, 2024
The Regulatory Stance on Oligonucleotide Enantiomers
Author(s)LCGC Editors
The panel dives into the regulatory stance on oligonucleotide enantiomers. The role of batch-to-batch reproducibility, new drug application (NDA) filing, and current guidelines are covered.
Advertisement
Episodes in this series
Regulatory guidelines must be considered when discussing oligonucleotide analysis and enantiomers. The panel reviews the current regulatory stance on this topic and common analytical bottlenecks relative to regulatory compliance.
Newsletter
Join the global community of analytical scientists who trust LCGC for insights on the latest techniques, trends, and expert solutions in chromatography.
Advertisement
Advertisement
Advertisement
Trending on LCGC International
1
Riva Returns Alive and Kicking
2
Chromatographic Profiling and Antibacterial Activity of Solvent-Extracted Shiitake Mushroom Compounds
3
Restek Introduces GC Columns Featuring TriMax Technology for Trace-level Sensitivity
4
Exercise-Induced Gut-Brain Axis Modulation in Autism: Insights from Chromatographic Metabolite Analysis
5